EU Clinical Trial 2015-003166-91

A phase II, open-label, non-controlled, intra-patient dose escalation study to characterize the pharmacokinetics after oral administration of eltrombopag in pediatric patients with refractory, relapsed or treatment naïve severe aplastic anemia or recurrent aplastic anemia.  May 22, 2019

Main objective of the trial: To characterize the PK of eltrombopag at steady state after oral administration in pediatric patients with SAA.

Parties

Investigators
Sponsors
Countries
EU GB HK NL PT RU US
Keywords
Aplastic anaemia ELTROMBOPAG ETB115 Eltrombopag REVOLADE

JSON preview

Similar records

Title

Source:  EMA Last updated:  May 30, 2019

From ClinicalTrialsRegister.eu, a database of the European Medicines Agency. This record may not reflect the most current and accurate data available from the EMA.